On October 26, 2021 Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, reported that Company Scientific Advisory Board Member, Dr. Yonina Tova (MD), an internationally recognized Radiation Oncologist, will be attending the American Society of Radiologic Technologists (ASRT) Radiation Therapy Conference (RTC) in Chicago on October 26, 2021 (Press release, Cannabics Pharmaceuticals, OCT 26, 2021, View Source [SID1234591986]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Company Director and Head of Advisory Board, Dr. Gil Feiler, commented: "Radiation therapy and chemoradiation therapy are part of the standard of care neoadjuvant treatments available for cancer patients. Our colorectal cancer treatment drug candidate RCC-33 could potentially improve the standard of care for neoadjuvant treatment by incorporating our cannabinoid-based neoadjuvant treatment into the standard of care. Parties interested in contacting or meeting with Cannabics Pharmaceuticals, and for more information on our colorectal cancer drug candidate RCC-33, please contact us at: [email protected]".

Read more:

Recent expansion of Company’s IP Portfolio with filing of 2 new Provisional Patents; Recent expansion of Cannabics Pharmaceuticals’ Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.); Recent expansion of Cannabics Pharmaceuticals’ Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors.

On October 26, 2021 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that it will report its 2021 third quarter financial results on Tuesday, November 9, 2021 after the close of the U.S. financial markets (Press release, Jazz Pharmaceuticals, OCT 26, 2021, View Source [SID1234591985]). Company management will host a live audio webcast at 4:30 p.m. ET/9:30 p.m. IST to discuss 2021 third quarter financial results and provide a business and financial update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharma.com.

On October 26, 2021 Nektar Therapeutics (Nasdaq: NKTR) reported that it will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S.-based financial markets (Press release, Nektar Therapeutics, OCT 26, 2021, View Source [SID1234591984]). Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: View Source The web broadcast of the conference call will be available for replay through December 6, 2021.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S); (970) 315-0453 (international)
Conference ID: 8264398 (Nektar Therapeutics is the host)

On October 26, 2021 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy (Press release, Personalis, OCT 26, 2021, View Source [SID1234591983]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first patent, US Patent No. 11,142,802, entitled "Methods for Using Mosaicism in Nucleic Acids Sampled Distal to Their Origin", issued on October 12, 2021. The ‘802 patent claims novel methods for identifying cancer mutations by comparing the sequence of cell-free nucleic acids found in the plasma to the individual’s "normal" genome, obtained from leukocytes or PBMCs, also isolated from the blood sample.

For later stage cancer patients with substantial tumor DNA in their plasma, this comparison helps discriminate true somatic variants from those of their germline genome. For earlier stage patients, with much less tumor DNA in their plasma, this method can help discriminate tumor variants from mosaicism elsewhere in the body, often referred to as CHIP.

The second patent, US Patent No. 11,155,867, entitled "Methods and Systems for Genetic Analysis", issued on October 26, 2021. The ‘867 patent claims a novel method for the deep sequencing of a clinically-relevant exome from a cell-free nucleic acid sample. The sequencing is accomplished using capture probe techniques that target one or more genomic features, which might be missed if using just a standard exome. This technology may reveal more of the cancer biology of a patient, enabling new drug development insights or better treatment options. As the liquid biopsy field moves on from first generation small panels to next generation exome scale, and drives towards higher sensitivity, these methods will become increasingly important.

Both the ‘867 and ‘802 patents are members of broader patent families that relate to Personalis’ early work relating to exome-wide analysis and the cell-free detection of disease. These families claim priority to applications filed in 2013 and 2014, respectively.

"We are pleased that the USPTO has recognized Personalis’ continued innovation for the exome-scale, cell-free detection of nucleic acids for the detection of disease," said Dr. Leslie Grab, VP of Intellectual Property at Personalis. "The issuance of these patents further strengthens the company’s significant intellectual property estate in the field of advanced cancer detection and analysis." To date, Personalis has been granted 18 US and foreign patents relating to advanced genomic sequencing and analysis solutions. In addition, the company has over 25 pending US and foreign patent applications that relate to its existing advanced cancer detection platforms as well as novel research areas, including methods for interpreting genetic data generated by its platforms.

"For over ten years, Personalis has been focused on innovation," said John West, Personalis’ Chief Executive Officer. "Our IP portfolio now spans 16 families, which cover important areas including liquid biopsy methods, personalized genetic testing, advanced biomarkers based on neoantigen characterization and HLA-loss, and more."

On October 26, 2021 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported the publication of its study "Precision neoantigen discovery using large-scale immunopeptidomes and composite modeling of MHC peptide presentation," in the Immunopeptidomics Special Issue of the journal Molecular & Cellular Proteomics (Press release, Personalis, OCT 26, 2021, View Source [SID1234591982]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Personalis authors created Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), a novel pan-allelic machine learning algorithm for predicting MHC-peptide binding and presentation that demonstrates significantly improved performance compared to currently available prediction tools. To improve performance and generalizability, SHERPA was trained with immunopeptidomics data from newly engineered cell lines mono-allelic for HLA combined with other publicly available datasets. In addition, SHERPA was designed to more comprehensively capture epitope binding and presentation features to further enhance the predictive power of the algorithm. Using a composite model constructed with gradient boosting decision trees, multi-allelic deconvolution, and 2.15 million peptides encompassing 167 unique human HLA alleles, SHERPA achieved a 1.44-fold improvement of positive predictive value compared to existing tools when evaluated on independent mono-allelic datasets. Since publication, Personalis has further expanded the in-house generated immunopeptidomics training data set to a total of ~70 mono-allelic cell lines, resulting in a new version of SHERPA with further enhanced performance.

"Integrating data from diverse cell lines and tissue types improved the generalizability of our models compared to other in silico methods, a critically important aspect when applying our models to patient samples. With a high degree of accuracy, SHERPA has the potential to enable higher accuracy neoantigen binding prediction for many clinical applications," said Richard Chen, MD, Personalis’ CMO and SVP of R&D. "With this advancement, SHERPA is expected to facilitate the discovery of more predictive biomarkers for cancer therapy as well as empower the development of neoantigen-targeting, personalized cancer therapies. Our recently published NEOPS biomarker is one example of a SHERPA-derived composite biomarker that has shown promise in predicting immunotherapy response in cancer patients."